Last reviewed 2026-06-02 · How we verify

FP-025 capsules

Foresee Pharmaceuticals Co., Ltd. · Phase 2 active Small molecule ✓ Verified Jun 2026 Quality 10/100

FP-025 capsules is a Small molecule drug developed by Foresee Pharmaceuticals Co., Ltd.. It is currently in Phase 2 development. Also known as: Adermastat, Placebo.

FP-025 capsules are a small molecule intervention being studied for their effects on allergen-induced airway responses in mild eosinophilic house dust mite-allergic asthma. The capsules are being investigated in clinical trials, including one registered on ClinicalTrials.gov as NCT03858686, where they are being compared to a placebo.

Likelihood of approval

15.3% vs 15.3% industry baseline

If approved by FDA: likely 2031–2034

Steps remaining: Phase 3 → NDA/BLA submission

Confidence: Medium

Why this estimate

Baseline phase 2 → approval rate +15.3pp
Industry-wide phase 2 drugs reach approval ~15.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).

Predicted approval windows by jurisdiction (conditional on FDA approval)

Regulator	Country	Likely year	Lag vs FDA
FDA	US	2031–2034	—
EMA	EU	2032–2035	+0.7 yr
MHRA	GB	2032–2035	+0.7 yr
Health Canada	CA	2032–2036	+0.9 yr
TGA	AU	2032–2036	+1.2 yr
PMDA	JP	2032–2036	+1.5 yr
NMPA	CN	2033–2037	+2.3 yr
MFDS	KR	2032–2036	+1.4 yr
CDSCO	IN	2032–2037	+1.8 yr
ANVISA	BR	2033–2037	+2.3 yr

Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).

Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.

At a glance

Generic name	FP-025 capsules
Also known as	Adermastat, Placebo
Sponsor	Foresee Pharmaceuticals Co., Ltd.
Modality	Small molecule
Phase	Phase 2

Approved indications

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

FP-025 capsules CI brief — competitive landscape report
FP-025 capsules updates RSS · CI watch RSS
Foresee Pharmaceuticals Co., Ltd. portfolio CI

Frequently asked questions about FP-025 capsules

What is FP-025 capsules?

FP-025 capsules is a Small molecule drug developed by Foresee Pharmaceuticals Co., Ltd..

Who makes FP-025 capsules?

FP-025 capsules is developed by Foresee Pharmaceuticals Co., Ltd. (see full Foresee Pharmaceuticals Co., Ltd. pipeline at /company/foresee-pharmaceuticals-co-ltd).

Is FP-025 capsules also known as anything else?

FP-025 capsules is also known as Adermastat, Placebo.

What development phase is FP-025 capsules in?

FP-025 capsules is in Phase 2.

Manufacturer: Foresee Pharmaceuticals Co., Ltd. — full pipeline
Also known as: Adermastat, Placebo

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing